BD Vacutainer Serum Blood Collection Tubes; BD Vacutainer Rapid Serum Tubes (RST)
Becton Dickinson and Company · Decision date Oct 16, 2026
What did the FDA decide?
FDA's 510(k) database records K252344 for BD Vacutainer® Serum Blood Collection Tubes and BD Vacutainer® Rapid Serum Tubes (RST), filed by Becton, Dickinson and Company of Franklin Lakes, New Jersey. The device falls under classification name Tubes, Vials, Systems, Serum Separators, Blood Collection, regulation 21 CFR 862.1675, product code JKA, in the Clinical Chemistry specialty and review panel. The record lists a Traditional submission, received 07/28/2025, not reviewed by a third party, not a combination product, and without an authorized Predetermined Change Control Plan.
On 10/16/2026 FDA recorded the decision as Substantially Equivalent (SESE), which is 510(k) clearance rather than premarket approval. The record does not identify which tube configurations, components or modifications were the subject of the submission, and no summary statement is present in the supplied data. The clinical basis for the equivalence determination, any performance data, and the specific indications are not available here and would need the underlying FDA documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Oct 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K252344
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Becton Dickinson and Company
- Product code
- JKA
- Decision code
- SESE
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Tubes, Vials, Systems, Serum Separators, Blood Collection.
- Applicant
- Becton Dickinson and Company
- Product code
- JKA
- FDA device class
- 2
FDA decision timeline
K252344 received
Application receipt date recorded by FDA.
K252344 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JKA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| CMT Health PTE., Ltd. | 510(k) clearance | Oct 28, 2026 | FDA | |
| Sol-Millennium Medical, Inc. | 510(k) clearance | Oct 21, 2026 | FDA | |
| CMT Health PTE., Ltd. | 510(k) clearance | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Becton Dickinson and Company
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Franklin Lakes, NJ
Sources and methodology
- Original FDA record: K252344
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

